OncLive TV

Neal D. Shore, MD, FACS, discusses an analysis of degarelix and luteinising hormone-releasing hormone (LHRH) agonists in prostate cancer.

Jeffrey S. Weber, MD, PhD, from the Moffitt Cancer Center and Research Institute, discusses sequencing immunologic and targeted therapies in patients with advanced BRAF-mutated melanoma.

Minetta Liu, MD, Breast Cancer Specialist, Mayo Clinic, Rochester, Minnesota, discusses the use of circulating tumor cells (CTCs) for prognosis and prediction in patients with breast cancer.

Constance D. Lehman, MD, PhD, from the Seattle Cancer Care Alliance, discusses breast imaging across various cancer centers.

Gypsyamber D'Souza, PhD, MPH, MS, an associate professor of epidemiology at Johns Hopkins University, comments on screening for HPV-related cancers.

Elizabeth Mittendorf, MD, PhD, from MD Anderson Cancer Center, discusses the use of peptide vaccines for the treatment of breast cancer.

Lead author, Alice T. Shaw, MD, PhD, from the Massachusetts General Hospital, reviews the first published results from a randomized phase III trial investigating crizotinib in patients with ALK-positive non-small cell lung cancer.

Suzanne A. W. Fuqua, PhD, professor of medicine at Baylor College of Medicine, discusses the androgen receptor in breast cancer.

Suresh S. Ramalingam, MD, from the Winship Cancer Institute of Emory University, discusses the role of heat shock proteins in normal cells and their potential role in treating cancer.

Alan P. Venook, MD, a professor in the Department of Medicine (Hematology/Oncology) at the University of California, San Francisco, discusses the importance of utilizing frailty index and geriatric assessments for patients with cancer.

Daniel J. George, MD, from the Duke Cancer Institute, discusses the potential to incorporate radium-223 into combination strategies to treat patients with metastatic castation-resistant prostate cancer.

Primo Lara, MD, and his son, Matthew Stephen Lara, discuss an analysis of predictors of survival for younger patients with non-small cell lung cancer.

Howard L. Kaufman, MD, Rush University Medical Center, discusses the implications of the Immunoscore for the treatment of patients with cancer.

Sandra Swain, MD, medical director of the Washington Cancer Institute at MedStar Washington Hospital Center, highlights information presented at the 2013 American Society of Clinical Oncology (ASCO) Meeting.

Charles J. Link, Jr, MD, from the Cancer Center of Iowa and NewLink Genetics, discusses the phase II trial of algenpantucel-L for pancreatic cancer.

A. Oliver Sartor, MD, Director of the Tulane Cancer Center, describes the mechanism of action of radium-223 for bone metastases from prostate cancer.

Josep Tabernero, MD, PhD, from the Vall d'Hebron University Hospital, believes that in order to treat patients with gastrointestinal cancers more effectively, researchers must focus on the molecular classification of particular subpopulations.

Andrew D. Seidman, MD, from Weill Cornell Cancer Center and Memorial Sloan-Kettering Cancer Center, discusses less surgery for patients with breast cancer.

Keerthi Gogineni, MD, MSHP, medical oncologist, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, comments on oncology drug shortages in the U.S.

Timothy S. Pardee, MD, describes a phase I trial looking at the first-in-class mitochondrial metabolism inhibitor CPI-613 in patients with advanced hematologic malignancies.

Nicholas J. Vogelzang, MD, from the University of Nevada School of Medicine, describes two additional analyses of the phase III ALSYMPCA trial.

Electra D. Paskett, PhD, Professor, College of Medicine, The Ohio State University, discusses the use of vinegar as a cervical cancer screening tool in the U.S.

Bruce Roth, MD, from the Siteman Cancer Center, Washington University School of Medicine, discusses the optimism for a cure with immunotherapies.

Agustin A. Garcia, MD, from the Keck School of Medicine of the University of Southern California, discusses a phase I trial analyzing the PARP inhibitor veliparib (ABT-888) in patients with breast cancer.

Lynn M. Schuchter, MD, Chief, Hematology Oncology, Department of Medicine, University of Pennsylvania, discusses the treatment of advanced melanoma.

Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses the treatment of ovarian cancer with PARP inhibitors.

Andrew T. Parsa MD, PhD, from the University of California, San Francisco, describes the design of a trial analyzing prophage G-200 vaccine for recurrent glioblastoma multiforme.

Renier J. Brentjens, MD, PhD, Leukemia Service, Memorial Sloan-Kettering Cancer Center, discusses the treatment of B-cell malignancies with chimeric antigen receptor(CAR)–modified T cells.

David R. Gandara, MD, from UC Davis Cancer Center, discusses treatment with the heat shock protein 90 inhibitor ganetespib.

Andrew D. Seidman, MD, from the Memorial Sloan-Kettering Cancer Center, describes his excitement over the genetic advances made in the treatment of patients with cancer.